Economists at the Centers for Medicare & Medicaid Services (CMS) project a slowdown in Medicare prescription drug spending growth between 2028 and 2033, attributable to drug price negotiation provisions under the Inflation Reduction Act. This anticipated reduction reflects the impact of policy measures aimed at curbing pharmaceutical costs for Medicare beneficiaries, signaling a potential shift in healthcare economics and payer dynamics.